Diabetes drug may significantly reduce risk of death

08/7/2008 | NYTimes.com

Results from the Accord clinical trial suggest the injectable drug Byetta may reduce the risk of death among people with Type 2 diabetes by as much as 75%, compared with patients on other diabetes medications. There is debate about the validity of the findings, however, and Eli Lilly and Co. and Amylin Pharmaceuticals, which market Byetta, have not publicized them.

View Full Article in:

NYTimes.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Actuary
Meridian Health Plan
Detroit, MI
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
President/Chief Executive Officer
MedCost
Winston-Salem, NC